Vir Biotechnology is handing off certain commercial rights for its hepatitis D program to European specialty pharma Norgine ...

The former director of the National Institutes of Health’s (NIH) National Institute of Allergy and Infectious Diseases (NIAID ...

Medline—the mammoth medical device distributor that has largely worked behind the scenes and out of the headlines to stock ...

“Built on years of global clinical use data, Versius Plus delivers the flexibility and intelligence today’s healthcare ...

After layoffs this fall, Mythic Therapeutics is winding down, putting all its assets up for sale and terminating its only ...

Medtronic reported that its new thrombectomy system, aimed at removing blood clots from the arms and legs, has begun its ...

Bristol Myers Squibb has become the latest Big Pharma to tie up a biotech pact as we reach the year’s end, tapping Harbour ...

University of California spinout Addition Therapeutics has uncloaked, revealing “breakthrough” PRINT technology it hopes will ...

Nektar Therapeutics is planning to bring its interleukin-2-targeting drug candidate into a phase 3 trial for severe alopecia ...

Vivek Ramaswamy has found time out of his campaign for governor of Ohio to launch a new biotech.  | Vivek Ramaswamy has found ...

A flurry of deal-making hasn’t let up as 2025 comes to a close, with Roche subsidiary Genentech getting in on the action and ...

Through a potential $1.37 billion deal, New York-headquartered Yarrow gains ex-China rights to a potential first-in-class ...